Wednesday, July 01, 2015 10:48:15 AM
Through its unique approach to product development, Mel-Mont Medical has developed a one-of-a-kind medical device kit that empowers women to test for cervical cancer. Unlike traditional screening using Pap smear, woman can now use XytoTest™ in a private setting to avoid the embarrassment, anxiety, or fear caused by the regular cytology. The key drivers of the Company's product development approach include: Private setting; No qualified personnel required; FDA approved DNA technology; 94% sensitivity reducing false negatives; Higher population coverage; and Cost-effectiveness. XytoTest™ is a self-sampling kit of cervical specimens for the analysis of DNA for the 14 high-risk strains of Human Papilloma Virus (HPV). Mel-Mont currently operates in the USA and emerging countries including in Latin and South America with a focus in Colombia, where the company has offices, and Mexico.
GVDI
Any post by budfoxhub is not a recommendation to buy, hold or sell a security.
FEATURED Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • Mar 18, 2024 8:51 AM
FEATURED Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • Mar 18, 2024 8:09 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM
PSYC Begins Business Overhaul Process with Consolidation of 10 Previously Issued Convertible Debentures • PSYC • Mar 13, 2024 7:13 AM